메뉴 건너뛰기




Volumn 21, Issue 2, 2013, Pages 599-607

Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: A UK cross-sectional survey

Author keywords

HRQL; Multiple myeloma; Quality of life; Treatment phase; Treatment free interval

Indexed keywords

ADULT; AGED; ARTICLE; BODY IMAGE; COGNITION; CROSS-SECTIONAL STUDY; EQ 5D; FEMALE; FUNCTIONAL STATUS; HEALTH CARE QUALITY; HEALTH IMPACT ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE CORE 30; QUALITY OF LIFE QUESTIONNAIRE MY20; QUESTIONNAIRE; SELF EVALUATION; SOCIAL INTERACTION; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT FREE INTERVAL; UNITED KINGDOM; VISUAL ANALOG SCALE;

EID: 84874110530     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1548-y     Document Type: Article
Times cited : (48)

References (28)
  • 3
    • 79958846304 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and management of multiple myeloma 2011
    • Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum 21569004 10.1111/j.1365-2141.2011.08573. x 1:CAS:528:DC%2BC3MXpsFWis7k%3D
    • Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32-75
    • (2011) Br J Haematol , vol.154 , pp. 32-75
    • Bird, J.M.1    Owen, R.G.2    D'Sa, S.3    Snowden, J.A.4    Pratt, G.5    Ashcroft, J.6    Yong, K.7    Cook, G.8    Feyler, S.9    Davies, F.10    Morgan, G.11    Cavenagh, J.12    Low, E.13    Behrens, J.14
  • 5
    • 84874112593 scopus 로고    scopus 로고
    • Cancer Research UK Accessed 20 Dec 2010
    • Cancer Research UK (2007) http://www.cancerresearchuk.org/. Accessed 20 Dec 2010
    • (2007)
  • 6
    • 34447266200 scopus 로고    scopus 로고
    • An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
    • EORTC Quality of Life Group 17574838 10.1016/j.ejca.2007.04.022 1:STN:280:DC%2BD2svhtFelsQ%3D%3D
    • Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J, EORTC Quality of Life Group (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43:1670-1678
    • (2007) Eur J Cancer , vol.43 , pp. 1670-1678
    • Cocks, K.1    Cohen, D.2    Wisløff, F.3    Sezer, O.4    Lee, S.5    Hippe, E.6    Gimsing, P.7    Turesson, I.8    Hajek, R.9    Smith, A.10    Graham, L.11    Phillips, A.12    Stead, M.13    Velikova, G.14    Brown, J.15
  • 8
    • 0031279593 scopus 로고    scopus 로고
    • Modelling valuations for EuroQol Health States
    • 9366889 10.1097/00005650-199711000-00002 1:STN:280:DyaK1c%2FjtlKrtg%3D%3D
    • Dolan P (1997) Modelling valuations for EuroQol Health States. Med Care 35:1095-1108
    • (1997) Med Care , vol.35 , pp. 1095-1108
    • Dolan, P.1
  • 9
    • 33644885460 scopus 로고    scopus 로고
    • Descriptive and prognostic value of patient-reported outcomes: The bortezomib experience in relapsed and refractory multiple myeloma
    • 16432077 10.1200/JCO.2005.04.0824 1:CAS:528:DC%2BD28Xitl2qt7k%3D
    • Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, de la Loge C (2006) Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 24:976-982
    • (2006) J Clin Oncol , vol.24 , pp. 976-982
    • Dubois, D.1    Dhawan, R.2    Van De Velde, H.3    Esseltine, D.4    Gupta, S.5    Viala, M.6    De La Loge, C.7
  • 10
    • 0025688231 scopus 로고
    • EuroQol - A new facility for the measurement of health-related quality of life
    • EuroQol Group 10.1016/0168-8510(90)90421-9
    • EuroQol Group (1990) EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
    • (1990) Health Policy , vol.16 , pp. 199-208
  • 15
    • 0003068836 scopus 로고    scopus 로고
    • The EuroQoL instrument: An index of health-related quality of life
    • Spilker (eds) 2 Lippincott-Raven Philadelphia
    • Kind P (1996) The EuroQoL instrument: An index of health-related quality of life. In: Spilker (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven, Philadelphia
    • (1996) Quality of Life and Pharmacoeconomics in Clinical Trials
    • Kind, P.1
  • 17
    • 70349126639 scopus 로고    scopus 로고
    • Health-related quality of life assessment in randomised controlled trials in multiple myeloma: A critical review of methodology and impact on treatment recommendations
    • 19558508 10.1111/j.1600-0609.2009.01303.x
    • Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F (2009) Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol 83:279-289
    • (2009) Eur J Haematol , vol.83 , pp. 279-289
    • Kvam, A.K.1    Fayers, P.2    Hjermstad, M.3    Gulbrandsen, N.4    Wisloff, F.5
  • 18
  • 22
    • 79955016800 scopus 로고    scopus 로고
    • Evidence-based mini-review: Treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation
    • American Society of Hematology. Education Program, 2010
    • Shah N, Lonial S (2010) Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2010: 310-313
    • (2010) Hematology/the Education Program of the American Society of Hematology , pp. 310-313
    • Shah, N.1    Lonial, S.2
  • 23
    • 0030945323 scopus 로고    scopus 로고
    • ABC of clinical haematology. Multiple myeloma and related conditions
    • 9099124 10.1136/bmj.314.7085.960 1:STN:280:DyaK2s3ltlyrtA%3D%3D
    • Singer CR (1997) ABC of clinical haematology. Multiple myeloma and related conditions. BMJ 314:960-963
    • (1997) BMJ , vol.314 , pp. 960-963
    • Singer, C.R.1
  • 24
    • 1642374858 scopus 로고    scopus 로고
    • Multiple myeloma
    • 15031034 10.1016/S0140-6736(04)15736-X
    • Sirohi B, Powles R (2004) Multiple myeloma. Lancet 363:875-887
    • (2004) Lancet , vol.363 , pp. 875-887
    • Sirohi, B.1    Powles, R.2
  • 25
    • 0032988090 scopus 로고    scopus 로고
    • Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European organization for research and treatment of cancer study group on quality of life
    • 10086801 10.1046/j.1365-2141.1999.01206.x 1:STN:280:DyaK1M7osVKjtw%3D%3D
    • Stead ML, Brown JM, Velikova G, Kaasa S, Wisløff F, Child JA, Hippe E, Hjorth M, Sezer O, Selby P (1999) Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European organization for research and treatment of cancer study group on quality of life. Br J Haematol 104:605-611
    • (1999) Br J Haematol , vol.104 , pp. 605-611
    • Stead, M.L.1    Brown, J.M.2    Velikova, G.3    Kaasa, S.4    Wisløff, F.5    Child, J.A.6    Hippe, E.7    Hjorth, M.8    Sezer, O.9    Selby, P.10
  • 26
    • 1942424107 scopus 로고    scopus 로고
    • A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; A prospective randomised phase III study
    • 15110879
    • van Agthoven M, Segeren CM, Buijt I, Uyl-De Groot CA, van der Holt B, Lokhorst HM, Sonneveld P (2004) A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer 40:1159-1169
    • (2004) Eur J Cancer , vol.40 , pp. 1159-1169
    • Van Agthoven, M.1    Segeren, C.M.2    Buijt, I.3    Uyl-De Groot, C.A.4    Van Der Holt, B.5    Lokhorst, H.M.6    Sonneveld, P.7
  • 28
    • 77955495783 scopus 로고    scopus 로고
    • Phase III study of the value of thalidomide added to melphalan plus prednisolone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 study
    • Dutch-Belgium Cooperative Group HOVON 10.1200/JCO.2009.26.1610 20516439 10.1200/JCO.2009.26.1610 1:CAS:528:DC%2BC3cXpslajtL8%3D
    • Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P, Dutch-Belgium Cooperative Group HOVON (2010) Phase III study of the value of thalidomide added to melphalan plus prednisolone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol 28:3160-3166. doi: 10.1200/JCO.2009.26.1610
    • (2010) J Clin Oncol , vol.28 , pp. 3160-3166
    • Wijermans, P.1    Schaafsma, M.2    Termorshuizen, F.3    Ammerlaan, R.4    Wittebol, S.5    Sinnige, H.6    Zweegman, S.7    Van Marwijk Kooy, M.8    Van Der Griend, R.9    Lokhorst, H.10    Sonneveld, P.11


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.